Location permission needed for a better experience.
EN
CV
MEMBERSHIPS
PUBLICATIONS
EDUCATION
  • 2018 İstanbul Medipol Üniversitesi Tıp Fakültesi / Kadın Hastalıkları ve Doğum Anabilim Dalı / Doçent Doktor
  • 2016 King`s College Hospital NHS Foundation Trust, Department of Obstetrics, Harris Birthright Research Center For Fetal Medicine - Fetal Medicine Research Institute, Londra, İngiltere / Perinatoloji Yan Dal Uzmanı
  • 2011 Erciyes Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum
  • 2005 Ankara Üniversitesi Tıp Fakültesi
EXPERIENCE
  • 2020 Acıbadem Sağlık Grubu
  • 2018 - 2020 Medipol Mega Üniversite Hastanesi / Kadın Hastalıkları ve Doğum Anabilim Dalı / Perinatoloji Kliniği
  • 2016 - 2018 İstanbul Sağlık Bilimleri Üniversitesi Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi / Perinatoloji Kliniği
  • 2013 - 2016 King`s College Hospital NHS Foundation Trust, Department of Obstetrics, Harris Birthright Research Center For Fetal Medicine - Fetal Medicine Research Institute, Londra, İngiltere
  • 2011 - 2013 Niğde Devlet Hastanesi / Kadın Hastalıkları ve Doğum Kliniği
MEMBERSHIPS
  • Türkiye Maternal-Fetal Tıp ve Perinatoloji Derneği
PUBLICATIONS
  • Maternal serum galectin-1 and galectin-3 levels in pregnancies complicated with preterm prelabor rupture of membranes The Journal of Maternal-Fetal & Neonatal Medicine, 2020, 33:5, 861-868, DOI: 10.1080/14767058.2019.1637409 Kaya B, Turhan U, Sezer S, Kaya S, Dag I, Tayyar A.
  • Type 4 laryngotracheoesophageal cleft detected during fetoscopic endoluminal tracheal occlusion in a fetus with severe congenital diaphragmatic hernia Ultrasound Obstet Gynecol. 2020, doi:10.1002/uog.20355 Yuksel, M.A. and Tayyar A,
  • The assessment of cardiac function with tissue Doppler imaging in fetuses with congenital diaphragmatic hernia The Journal of Maternal-Fetal & Neonatal Medicine, 2020, 33:7, 1233-1238, DOİ: 10.1080/14767058.2019.1674806 Kaya B, Tayyar A, Sezer S, Kaya S.
  • Maternal serum mitofusin-2 levels in patients with preeclampsia: the possible role of mitochondrial dysfunction in preeclampsia The Journal of Maternal-Fetal & Neonatal Medicine, 2019, DOI: 10.1080/14767058.2018.1532497 Aydogan BM, Yuksel I, Tayyar A, Aslan Cetin B, Tayyar AT, Koroglu N.
  • Wnt signaling pathway in early-and late-onset preeclampsia: evaluation with Dickkopf-1 and R-Spondin-3 glycoproteins Archives of gynecology and obstetrics. 2019 Jun 1;299(6):1551-6. Tayyar AT, Karakus R, Sahin ME, Topbas NF, Sahin E, Karakus S, Yalcın ET, Tayyar A.
  • Comparison of fetal cardiac functions between small-for-gestational age fetuses and late-onset growth-restricted fetuses Journal of Perinatal Medicine, 2019, DOI: https://doi.org/10.1515/jpm-2019-0206 Kaya B, Tayyar A, Kanber Acar D, Kaya S.
  • Assessment of fetal right ventricular myocardial performance index changes following intrauterine transfusion The Journal of Maternal-Fetal & Neonatal Medicine. 2019 Oct 12:1-4. Temel Yüksel İ, Acar D, Turhan U, Aslan Çetİn B, Köroğlu N, Şenol G, Tayyar A, Yüksel MA.
  • Perinatal outcomes of intrauterine transfusion for foetal anaemia due to red blood cell alloimmunisation Journal of Obstetrics and Gynaecology. 2019 Aug 26:1-5. Şavkli AÖ, Çetin BA, Acar Z, Özköse Z, Behram M, Çaypinar SS, Tayyar A, Yüksel MA.
  • Maternal serum sestrin 2 levels in preeclampsia and their relationship with the severity of the disease Hypertens Pregnancy, 2018, 1-7. doi:10.1080/10641955.2018.1540702 Tayyar, A. T., Tayyar, A., Kozali, S., Karakus, R., Eser, A., Abide Yayla, C., Yalcın ET, Dag I, Eroglu, M.
  • Increased maternal C1q/TNF-related protein-1 (CTRP-1) serum levels in pregnancies with preeclampsia The Journal of Maternal-Fetal Neonatal Medicine, 2018, Doi :10.1080/14767058.2018.1498838 Acar DK, Tayyar A, Yuksel A, Atıs A, Ekiz A, Topcu G.
  • Maternal cytoglobin (CYGB) serum levels in normal and preeclamptic pregnancies. The Journal of Maternal-Fetal Neonatal Medicine, 2018, Doi: 10.1080/14767058.2017.1421927 Tayyar AT, Tayyar A, Kozalı S, Karakus R, Karakus S, Temel YI, Dag Ismail, Yetkin Yildirim Gonca, Demirci Oya
  • Increased levels of the novel hepatokine fetuin B in patients with intrahepatic cholestasis of pregnancy. The Journal of Maternal-Fetal Neonatal Medicine 2017; 1-6., Doi: 10.1080/14767058.2017.1413546 Koroglu N, Tayyar A, Tola EN, Yetkin YG, Temel YI, Aslan Cetin B, Dag I, Acar DK.
  • Could first- and second-trimester biochemical markers for Down Syndrome have a role in predicting intrahepatic cholestasis of pregnancy? Archives of Medical Science 2017; Doi: 10.5114/aoms.2017.69865 Tayyar AT, Tayyar A, Atakul T, Yayla CA, Kilicci C, Eser A, Karakus R, Herkiloglu D, Cundubey C R, Tayyar M.
  • Evaluation of FGF-19 and Beta-Klotho as biomarkers in patients with intrahepatic cholestasis of pregnancy Archieves of Medical Science 2017; Doi: 10.5114/aoms.2017.72424 Tayyar AT, Tayyar A, Kozali S, Karakus R, Koroglu N, Temel Yuksel I, Yetkin Yildirim G, Dag I, Eroglu M
  • Upper limb hemimelia in a twin pregnancy which was obtained by an ICSI and PGD in a woman with mosaic Turners Syndrome and the prognosis. Organogenesis 2017;13(4), 179-182., Doi: 10.1080/15476278.2017.1358842 Tayyar AT, Tayyar A, Eser A, Kilicci C, Yenidede I, Selcuk S.
  • Maternal copeptin levels in intrahepatic cholestasis of pregnancy J Matern Fetal Neonatal Med. 2017 Jun; 14:1-5. doi: 10.1080/14767058.2017.1335708. Tayyar A, Temel Yuksel I, Koroglu N, Tayyar A.T, Davutoglu Alıcı E, Akkaya Fırat A, Aslan Cetin B.
  • Mean arterial pressure at 12, 22, 32 and 36 weeks gestation in screening for preeclampsia Ultrasound Obstet Gynecol. 2016 May;47(5):573-9. Tayyar A, Krinitakis K, Wright A, Wright D, Nicolaides KH.
  • Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015 Jun;45(6):689-97. Tayyar A, Guerra L, Wright A, Wright D, Nicolaides KH.
  • Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks'' gestation Fetal Diagn Ther. 2014;36(1):18-27. Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH.
  • Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks'' gestation. Fetal Diagn Ther. 2014;36(1):9-17. Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.

INFORMATION FORM WITH REGARD TO OBTAINING AND PROCESSING OF PERSONAL DATA

Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. (“Acıbadem”) and Acıbadem’s controlling shareholders, parent companies and affiliates (hereinafter to be collectively referred to as “Acıbadem Group”) may, acting as “Data Supervisor” under the Law on Protection of Personal Data no. 6698 (the “Law”) and other pertinent laws and regulations, process your personal data within the following frame and in strict compliance with the Basic Healthcare Services Law no. 3359, the Governmental Decree-Law on Organization and Duties of the Ministry of Health and its Affiliated Companies no. 663, the Private Hospitals Regulation, and other regulations of the Ministry of Health, and other applicable laws and provisions.

1. Obtaining and Processing of Personal Data, and Purposes of Processing:

Your personal data is collected and obtained verbally, in writing, or in visual or electronic media, through call center, internet site, verbally, in writing or similar other channels for conduct of such services as protection of public health, preventive medicine, medical diagnosis, treatment and maintenance services offered by Acıbadem Group, or for planning and management of healthcare services and financing, and in accordance with the fields of business of Acıbadem Group Companies. Your general personal data and special personal data, especially your healthcare data, may be processed by the Group to a limited extent for all and any purposes, including, but not limited to, the following purposes:

All kinds of your personal data obtained by Acıbadem Group (including, but not limited to, your special personal data) may be processed for the following purposes:

Your personal data obtained and processed pursuant to the applicable laws and regulations may be transferred to physical archives and/or information systems of Acıbadem or Acıbadem Group and may be kept and stored both in digital and in physical platforms.

2. Transfer of Personal Data

Your personal data may be shared by Acıbadem and Acıbadem Group with companies included in Acıbadem Group or with private insurance companies, Ministry of Health and its sub-units, Social Security Agency, Security General Directorate and other security forces, General Directorate of Population and Census, Turkish Pharmacists’ Association, courts and all kinds of other juridical authorities, central etc. third parties, your authorized representatives and agents, and third parties offering consulting and advice services to us, including, but not limited to, lawyers, tax and financial consultants and auditors, and our business partners and other third parties acting in cooperation with us for further development or performance of healthcare services for the purposes cited above, also including regulatory and supervisory bodies and authorities, and official authorities, for the purposes of processing listed above, in accordance with the Law and other applicable laws and regulations.

3. Methods and Legal Causes of Obtaining of Personal Data

Your personal data are collected and processed in all kinds of verbal, written, visual or electronic media, for the purposes listed hereinabove, and for performance of all kinds of works included in the fields of business of Acıbadem within the legal framework, and accordingly, for full and proper performance of all kinds of contractual and legal duties and obligations of Acıbadem. Legal causes of collection and acquisition of your personal data are the pertinent provisions of:

Furthermore, as stipulated in 3rd paragraph of article 6 of the Law, personal data relating to health may also be processed by persons under secrecy obligations or by authorized official entities and organizations, without being liable to receive prior explicit consent of the relevant purpose, only for protection of public health, preventive medicine, medical diagnosis, treatment and maintenance services, and for planning and management of healthcare services and financing.

4. Your Rights Regarding Protection of Personal Data

Pursuant to the Law and other relevant applicable laws and regulations, you are entitled:

If at any time you use any one or more of your aforesaid rights, the relevant information will be transmitted to you clearly and in an understandable manner, in writing or in electronic media, by using the communication data and information provided by you.

5. Data Security

Acıbadem protects your personal data in full and strict compliance with all technical and administrative security controls required to be taken in accordance with information security standards and procedures. Said security actions and measures are taken and provided at a level appropriate for the probable risks by also taking into consideration the technological possibilities.

6. Complaints and Communications

Your personal data are protected within the frame of the available technical and administrative possibilities, and the required security actions and measures are taken and provided at a level appropriate for the probable risks by also taking into consideration the technological possibilities.

By filling in the “Application Form Pursuant to the Law on Protection of Personal Data” given at the , “https://www.acibadem.com.tr/acibademonline/hastaverilerinkorunmasi.html” web address, you may transmit and submit your legal requests:

You are hereby kindly requested to transmit your legal requests under the Law by filling in the “Application Form Pursuant to the Law on Protection of Personal Data” given at the https://www.acibadem.com.tr/acibademonline/hastaverilerinkorunmasi.html web address and sending it to us by the communication means set forth in the form.

TOP
How can we help you?